The Pan-Immune-Inflammation Value is a new prognostic biomarker in metastatic colorectal cancer: results from a pooled-analysis of the Valentino and TRIBE first-line trials
Giovanni Fucà(AstraZeneca (Spain)), Filippo Pietrantonio(Fondazione IRCCS Istituto Nazionale dei Tumori), Filippo de Braud(University of Milan), Federica Marmorino(University of Pisa), Roberto Murialdo(Ospedale Policlinico San Martino), Roberto Moretto(Azienda Ospedaliera Universitaria Pisana), Andrea Sartore‐Bianchi(University of Milan), Vincenzo Guarini(Fondazione IRCCS Istituto Nazionale dei Tumori), Alberto Zaniboni(Fondazione Poliambulanza Istituto Ospedaliero), Sara Bustreo(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino), Sara Lonardi(Istituto Oncologico Veneto), Fotios Loupakis(Azienda Ospedaliera Universitaria Pisana), Vincenzo Adamo(University of Messina), Alessandra Boccaccino(Ospedale "Santa Maria delle Croci" di Ravenna), Giuseppe Tonini(Campus Bio Medico University Hospital), Federica Morano(Fondazione IRCCS Istituto Nazionale dei Tumori), Lorenza Rimassa(Humanitas University), Beatrice Borelli(University of Pisa), Salvatore Corallo(Fondazione IRCCS Istituto Nazionale dei Tumori), Marco Tampellini(Ospedale San Luigi Gonzaga), Carlotta Antoniotti(University of Pisa), Chiara Cremolini(University of Pisa), Enrico Cortesi(Sapienza University of Rome), Gianluca Tomasello(Istituti Ospitalieri di Cremona), Matteo Claravezza(Ente Ospedaliero Ospedali Galliera)
Cited by 350
Related Papers
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
|Science Translational Medicine|2014|5.1k
Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer
|Journal of Clinical Oncology|2000|3.8k
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
|The Lancet Oncology|2017|2.8k
Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer
|Journal of Clinical Oncology|2018|2.1k